Citations

Clear

35 citation(s) found for "Chan, Wing C".

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Hilton, Laura K. , Collinge, Brett , Alduaij, Waleed , Shaalan, Haya, Weng, Andrew P. , Cruz, Manuela Martins , Slack, Graham W. , Farinha, Pedro , Miyata‐Takata, Tomoko , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus, Fu, Kai , Delabie, Jan , Pittaluga, Stafania, Iqbal, Javeed , Wright, George, Staudt, Louis M. , Wright, George W. , Alduaij, Waleed , Weng, Andrew P , Farinha, Pedro , Boyle, Merrill , Cook, James R , Ondrejka, Sarah , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Jaffe, Elaine S , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Feldman, Andrew L , Steidl, Christian , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Wright, George , Hilton, Laura K , Ben‐Neriah, Susana , Cruz, Manuela, Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Sehn, Laurie H. , Savage, Kerry J. , Mungall, Andrew J. , Feldman, Andrew L. , Steidl, Christian , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood | May 3, 2024 | Volume: 144 | Issue: 5 | Pages: 525-540

10.1182/blood.2024024251 | PMID 38701426 Get It

Abstract Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study
Dasari, Surendra , Amador, Catalina, Chan, Wing C. , Cook, James R. , Farinha, Pedro , Fu, Kai , Greiner, Timothy C. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Staudt, Louis M. , Wright, George W. , Zeng, Yu , Yoshino, Tadashi, Wu, Xiaojun , Satou, Akira , Perry, Anamarija M. , Ko, Young Hyeh , Jiang, Liuyan , Chen, Weina , Chapman‐Fredricks, Jennifer R., Ansell, Stephen M. , Aljudi, Ahmed, Farinha, Pedro , Wright, George , Feldman, Andrew L. , Rimsza, Lisa M. , Scott, David W. , Oishi, Naoki , Campo, Elı́as , Delabie, Jan , Inghirami, Giorgio , Iqbal, Javeed , Jaffe, Elaine S. , Pittaluga, Stefania , Raess, Philipp W. , Savage, Kerry J. , Slager, Susan L. , Song, Joo Y. , Wang, Hao‐Wei , Wilcox, Ryan A. , Wang, Xueju , Miranda, Roberto N. , Medeiros, L. Jeffrey , Maurer, Matthew J. , Mou, Eric , Karube, Kennosuke , Kahl, Brad S. , Jaye, David L. , Leval, Laurence de , Cerhan, James R. , Barrionuevo, Carlos

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 847-847

10.1182/blood-2023-186969 Get It

Background: Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell lymphomas that share pathologic features but differ in clinical presentation, outcome, and molecular features. The World Health Organization (WHO) and International Consensus Classification (ICC) classify ALCLs by presence or absence of ALK rearrangements (R) and clinical presentation (systemic, cutaneous [c], or breast implant-associated [BIA]). ICC, but not WHO, recognizes DUSP22-R as defining a new genetic subtype of ALK- ALCL. The classifications otherwise do not reflect additional molecular heterogeneity in genetics (e.g., TP63-R) or therapeutic vulnerabilities (e.g., JAK-STAT3 pathway activation). Methods: ALCLs (N=689) underwent expert consensus review (WHO/ICC) through the Lymphoma/Leukemia Molecular Profiling Project (LLMPP). All cases also underwent genetic subtyping (ALK, DUSP22, TP63, and triple-negative [TN]) using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), as well as IHC for phospho-STAT3 Tyr705 (pSTAT3). RNAseq was performed and evaluable in 393 cases; the remaining cases had insufficient tissue, tumor content, RNA yield or quality, and/or sequencing data quality. Sequenced and non-sequenced sub-cohorts had similar demographics and subtype distribution. Results: Unsupervised gene expression profiling (GEP) identified 2 main molecular types of ALCL. Type I ALCLs predominantly included ALK+ ALCLs, BIA-ALCLs, and a subset of TN ALCLs (designated TN-I), whereas Type II ALCLs predominantly included ALCLs with DUSP22-R, TP63-R, or both (double-hit; DH), and the remaining TN ALCLs (TN-II). Type I ALCLs were strongly associated with pSTAT3 expression (74.2±26.4% positive malignant cells vs 9.9±22.7% for Type II; P<0.0001). An independently derived pSTAT3 staining threshold of 30% assigned Type I vs II with 91% accuracy. A third cluster of ALCLs, mostly cALCL, showed an epithelial GEP signature rather than a lymphoma signature; these cases were assigned to Types I or II based on pSTAT3 IHC. Distinct sub-signatures were identified for ALK+, DUSP22-R, TP63-R, and BIA ALCL (Fig. 1), but not ALK- ALCL or cALCL. Gene set enrichment analysis showed Type I ALCLs to be enriched for JAK-STAT3 signaling genes (normalized enrichment score [NES], 2.22; FDR<0.0001) and related pathways, such as TNFα-NFκB signaling (NES, 2.21; FDR<0.0001). In contrast, Type II ALCLs were enriched for cell cycle, DNA repair, epigenetic, and metabolic pathway genes, but not for major tyrosine kinase-mediated signaling pathway genes. Enriched epigenetic pathways included chromatin modifying enzymes (NES, -1.86; FDR=0.002) and histone methylation (NES, -1.71; FDR=0.002). EZH2 was the most overexpressed gene in Type II ALCLs (fold-change, 7.74; FDR=8.84×10 -306). At the protein level, EZH2 IHC H-scores were 275±45 in Type II and 168±70 in Type I ALCLs (P<0.0001); H3K27me3 H-scores were 170±81 and 76±63, respectively (P<0.001). The top metabolic gene set involved cholesterol biosynthesis (NES, -1.88; FDR=0.002). Overall survival (OS) data were available in 257 systemic ALCL patients (145 sequenced and 112 non-sequenced; cALCL and BIA-ALCL were excluded). Non-sequenced TN ALCLs were assigned to TN-I or TN-II using pSTAT3 IHC. The results supported earlier data indicating favorable prognosis of DUSP22-R ALCL (5 y OS, 95%) and ALK+ ALCL (87%), intermediate prognosis of TN ALCL (TN-I, 52% and TN-II, 38%; P=NS), and poor prognosis of TP63-R/DH ALCL (0%)(P<0.0001; Fig. 2). Conclusions: Two overarching molecular types of ALCL exist, predominantly associated with the presence (Type I) or absence (Type II) of the JAK-STAT3 signaling program. Distinct GEP signatures exist for ALK+ ALCL and BIA-ALCL (predominantly Type I), and DUSP22-R ALCL and TP63-R ALCL (predominantly Type II). TN ALCLs lacking ALK-R, DUSP22-R, and TP63-R can be stratified into TN-I and TN-II subtypes. pSTAT3 IHC has >90% accuracy as a surrogate for GEP-based subtyping. ALK- ALCL and cALCL cluster by molecular subtype rather than by defining GEP signatures. Type II ALCLs are enriched for targetable epigenetic and metabolic pathways, including EZH2/histone methylation and cholesterol biosynthesis. This molecular classification is diagnostically, prognostically, and potentially therapeutically relevant, and can be applied using FISH and IHC in routine practice and in the clinical trial setting.
Genomic Stability, DNA Repair and the SKP1-CUL1-F-Box Complex in HIV Associated Diffuse Large B-Cell Lymphoma
Armitage, Lindsey, Carvalho, Pedro S. de , Wisner, Lee, Chan, Wing C. , Chapman‐Fredricks, Jennifer R., Jager, Louis de , Leal, Fábio E. , Maguire, Alanna , Maguire, Alanna , Maguire, Alanna , Gibson, Sarah E. , Song, Joo Y. , Vega, Francisco , Pileri, Stefano , Rimsza, Lisa M.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 2991-2991

10.1182/blood-2023-182953 Get It

Introduction: Previously we demonstrated that HIV associated diffuse large B-cell lymphomas (DLBCL) of Germinal Center B-cell subtype (GCB) are more proliferative, with enhanced genomic stability and increased expression of DNA repair genes, particularly Fanconi anemia (FA) and homologous recombination (HR) genes compared to their HIV negative counterparts (Maguire et al, 2019). It is unknown if this signature is unique to the GCB subtype or if it is also observed in Activated B-cell (ABC) and Unclassified (UNC) DLBCL. Herein we validate our HIV associated GCB DLBCL findings in a larger independent cohort and report for the first time the aberrational profile of molecularly profiled HIV associated ABC DLBCL compared to their HIV negative counterparts respectively. Methods: An independent cohort of 353 DLBCL FFPE cases was assembled, including 125 HIV-DLBCL samples. All samples underwent hematopathological review to confirm diagnosis and determine tumor content. Samples with <60% tumor content were macro-dissected before they were RNA/DNA extracted. Cell of origin (COO) profiles were assessed using the Lymph3Cx molecular assay which can distinguish primary mediastinal B-cell lymphoma (PMBL) like from GCB, ABC and UNC DLBCL (Mottok et al 2018). Copy number (CN) analyses were performed on samples with sufficient DNA (41 HIV neg, 32 HIV pos) using the OncoScan FFPE assay kit and the resulting data analyzed using Chromosome Analysis Suite (ChAS) v4.1 and the multisample viewer module of Reproductive Health Research Analysis Software (RHAS) v1.1. Additional digital gene expression profiling was performed using the Pan-Cancer panel (NanoString, Seattle, WA) customized to include 9 BCL2 family genes for a total of 739 genes and analyzed using the NanoString nSolver Advanced Analysis module. Results: GCB, ABC, UNC and PMBL-like proportions were 50%, 30%, 14% and 6% in HIV unassociated (HIV neg) and 50%, 23%, 25% and 2% in HIV pos tumors respectively, confirming both cohorts were GCB-enriched by molecular profiling. PMBL-like cases were excluded from further analyses. OncoScan CN analyses showed that HIV pos DLBCL were significantly less aberrant than HIV neg DLBCL (median CN per sample 0.56 vs 1.01, p<0.001). HIV pos GCB tumors were significantly less aberrant than both HIV neg GCB tumors (median CN per sample 0.50 vs 1.11, p<0.001), and HIV pos ABC tumors (median CN per sample 0.50 vs 0.81, p=0.009). HIV pos ABC tumors were also less aberrant than HIV neg ABC tumors, however, the difference was not significant overall (median CN per sample 0.81 vs 1.03, p=0.162) or for gain/amplifications (median CN per sample 0.38 vs 0.42, p=0.814), but was borderline significant for loss/deletions (median CN per sample 0.31 vs 0.47, p=0.06). GEP analyses identified Cell Cycle and DNA repair as the top two upregulated pathways in HIV pos GCB tumors compared to HIV neg GCB tumors. In contrast, Cell Cycle and DNA repair were downregulated in HIV pos ABC tumors compared to HIV neg ABC tumors. However, one gene ( RBX1) was identified as significantly upregulated in both pathways in HIV pos GCB (adjusted p-value 0.0215) and HIV pos ABC (adjusted p-value 0.0046) tumors compared to their HIV neg counterparts. A second gene ( SKP1) was also significantly upregulated in HIV pos GCB (adjusted p-value 3.94E-5) and HIV pos ABC (adjusted p-value 0.0031) tumors. Together RBX1 and SKP1 encode the two principal functional subunits of the SKP1, CUL1, F-box protein (SCF) complex which is part of the ubiquitin proteasome system (UPS) and has been reported as essential for maintaining genome and chromosome stability (Thompson et al 2021). Conclusions: These results demonstrate that HIV pos DLBCL tumors are less aberrant than their HIV neg counterparts irrespective of COO subtype. However, the degree of genomic stability differs by COO, with HIV pos GCB tumors being more genomically stable than HIV pos ABC tumors. Although both have enhanced expression of UPS related SCF genes ( RBX1, SKP1), only HIV pos GCB tumors have enhanced expression of key DNA repair genes as well including Fanconi Anemia ( BRCA2/FANCD1, FANCL) and mismatch repair ( MSH2, MSH6) genes (adjusted p-values of ≤ 0.0263). Given the reported role of SCF in genomic stability maintenance, the HIV pos COO CN differences could be due to the contributions of both DNA repair and SCF mechanisms in HIV pos GCB and mainly SCF mechanisms in HIV pos ABC tumors.
Refining Diagnostic Subtypes of Peripheral T-Cell Lymphoma Using a Multiparameter Approach
Weisenburger, Dennis D. , Gomez, Ana, Cook, James R. , Greiner, Timothy C. , Ondrejka, Sarah L. , Ott, German , Özkaya, Neval , Rosenwald, Andreas , Slack, Graham W. , Chan, Wing C. , Amador, Catalina , Bouska, Alyssa , Vega, Francisco , Feldman, Andrew L. , Jaffe, Elaine S. , Raess, Philipp W. , Savage, Kerry J. , Song, Joo Y. , Rimsza, Lisa M. , Iqbal, Javeed

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 1636-1636

10.1182/blood-2023-186950 Get It

Peripheral T-cell lymphoma (PTCL) encompasses a diverse group of post-thymic lymphomas, with ~40% of cases not further classifiable and designated as PTCL-not otherwise specified (PTCL-NOS). Two molecular prognostic subtypes of PTCL-NOS, PTCL-TBX21 and PTCL-GATA3, were identified through gene expression profiling (GEP). A subset of PTCL-NOS with T-follicular helper (TFH) differentiation was subsequently categorized as nodal PTCL with TFH phenotype (PTCL-TFH), also known in current classifications as nodal PTCL-TFH, NOS, or TFH lymphoma, NOS. However, the boundary between PTCL-NOS and PTCL-TFH remains poorly defined. To refine these subtypes, 101 PTCL-NOS with centralized pathology review and extensive immunophenotyping by immunohistochemistry (IHC) using 22 antibodies, digital GEP (nCounter, NanoString Inc) (n= 70), and RNA sequencing (n= 73) were included in this study. IHC was used to identify PTCL-TFH cases (those with strong expression of more than two TFH markers); the remaining patients were classified as PTCL-GATA3 and PTCL-TBX21 using pre-defined GEP signatures. Cases were reclassified into PTCL-NOS (n= 63) and PTCL-TFH (n= 38), with PTCL-NOS subclassified into PTCL-GATA3 (n= 22; 34%) and PTCL-TBX21 (n= 41; 66%) and showing significant differences in OS (p<0.001). PTCL-GATA3 was characterized by medium to large transformed cells (average= 90%, 70-100%) and had minimal tumor microenvironment (TME) (TME-poor: 100%). In contrast, PTCL-TBX21 was more heterogeneous, associated with pleomorphic cells in a polymorphous background (TME-rich: 78%), including Lennert lymphoma-like cases (22%). mRNA and CIBERSORT analysis substantiated the findings and identified a subset enriched in cytotoxic features in the PTCL-TBX21 subtype. IHC indicated that PTCL-GATA3 cases were CD4+/CD8- (83%) or CD4-/CD8- (17%) and lacked expression of CD8 or cytotoxic markers compared to PTCL-TBX21 (p<0.01). PTCL-GATA3 showed significantly higher expression of LEF1 (average= 80%), Ki67 (80%), and MYC (25%) than PTCL-TBX21 (25%, 30%, <5%, respectively, p<0.01). mRNA and protein expression of these biomarkers showed a significant positive correlation (r=0.5, p<0.001), and expectedly higher mRNA expression of LEF1 and MYC was observed in the PTCL-GATA3 versus PTCL-TBX21 (p<0.05). Strong expression of CD30 (>50% of cells) was only seen in PTCL-GATA3 cases. EBER positivity, found only in rare background cells, was not significantly different (18% of PTCL-GATA3 vs. 12% of PTCL-TBX21). Within PTCL-TBX21, we identified cytotoxic and non-cytotoxic subsets with divergent morphological, phenotypic, and clinical findings. The cytotoxic PTCL-TBX21 exhibited an activated cytotoxic phenotype (23/25, 96%), denoted by TIA1 and granzyme-B and/or perforin expression. Extranodal involvement and single-cell apoptosis were observed in 17% and 45% of the cytotoxic cases, respectively, but absent in non-cytotoxic PTCL-TBX21 cases. A trend towards higher Ki67 expression (average= 40% vs. 20%, p= 0.08) was seen in the cytotoxic subgroup. In contrast, the non-cytotoxic PTCL-TBX21 was associated with a CD4+/CD8- phenotype and higher ICOS expression (average= 30%) and CCR4 (60%) compared to the cytotoxic PTCL-TBX21 (p= 0.001). PTCL-TFH cases showed a CD4+/CD8- phenotype (90%) and rarely a CD4-/CD8- phenotype (10%). While a subset of PTCL-TFH cases had AITL-like features such as numerous clear cells and/or prominent vasculature (31% of cases), which were not seen in the other subgroups, the remaining cases exhibited morphology that was indistinguishable from other PTLC-NOS cases including sheets of transformed cells or pleomorphic cells in a polymorphous background. Morphologically, PTCL-TFH cases, like PTCL-TBX21 were associated with a rich TME (TME-rich: 75%). CIBERSORT analysis showed enrichment of plasma cells (p<0.01) in PTCL-TFH, compared to PTCL-TBX21, and validated by morphology (30% of cases vs. 5%). Expression of one TFH marker was frequent in some PTCL-NOS cases (PTCL-GATA3= 41% of cases, PTCL-TBX21-non cytotoxic= 47%, PTCL-TBX21-cytotoxic= 5%). Conclusion: Our comprehensive evaluation underscores the importance of integrating morphology, immunophenotyping, and GEP in achieving an accurate diagnosis, potentially leading to more tailored treatment strategies for PTCL. Correlation with pending whole-exome sequencing studies will be provided at the time of presentation.
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
Zhang, Weiwei , Sharma, Sunandini , Heavican‐Foral, Tayla B. , Cannatella, Jeffrey J. , Amador, Catalina, Arif, Aiza, Lim, Soon Thye , Du, Ming‐Qing , Greiner, Timothy C. , Fu, Kai , Trøen, Gunhild, Weinstock, David M. , Laginestra, Antonella, Kim, Kyeongjin , Weisenburger, Dennis D. , Davé, Sandeep S. , Chan, Wing C. , Bouska, Alyssa , Holte, Harald , Shah, Ab Rauf , Lone, Waseem , Cappelli, Luca Vincenzo , Fiore, Danilo , Gong, Qiang , Heavican, Tayla B., Smith, Lynette M. , Ong, Choon Kiat , Feldman, Andrew L. , Leval, Laurence de , Vodák, Daniel , Nakken, Sigve , Delabie, Jan , Pileri, Stefano , Pajvani, Utpal B. , Vose, Julie M. , Inghirami, Giorgio , Iqbal, Javeed

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 2993-2993

10.1182/blood-2023-186530 Get It

Follicular helper T-cell lymphoma of the angioimmunoblastic type (AITL) is associated with dismal prognosis. We performed functional genomic approaches including whole-exome sequencing (WES; n=119), transcriptomic (n=78) and methylation (n=40) analysis. We identified recurrent mutations in known epigenetic drivers ( TET2, DNMT3A, IDH2 R172), and also identified novel ones (TET3, KMT2D). Somatic mutation of all three epigenetic drivers ( TET2, IDH2, and DNMT3A) was associated with poor prognosis (p<.001). Mutations in genes regulating T-cell receptor (TCR) signaling ( CD28 VAV1, FYN, PLCG1) or activation ( RHOA G17V), and regulators of the PI3K pathway (PIK(3)C members, PTEN,PHLPP-1/-2) were also found. Genome-wide DNA-methylation analysis integrated with mRNA expression profiling also revealed epigenetic alterations in genes regulating TCR-RHOA/B/C or PI3K-signaling. TET2 loss was noted in 85% AITLs and was significantly associated with RHOA G17V, CD28 and IDH2 R172mutations. AITLs lacking RHOA G17V tended to have mutations regulating the JAK-STAT pathway ( JAK2, JAK3, STAT1, STAT3, SOCS1). RNA-seq analysis identified fusion transcripts in genes regulating TCR activation (8%), revealed a restricted TCR repertoire in the majority of cases (a=87%, b=72%), and showed the presence of Epstein-Barr virus transcriptome (73%). GEP demonstrated association of B-cells in the tumor-milieu with better prognosis (p=.006), while dendritic cells were associated with worse prognosis (p=.001), which was further validated by immunohistochemistry using CD20, CD68, and CD163 antibodies. RNA-seq and corresponding WES analysis of 12 AITL patient-derived-xenografts (PDX) showed that bi-allelic TET2 mutations, DNMT3A mutations or sub-clonal mutations ( PLCG1 PHLPP2) werepropagated in sequential passages. Gene signatures related to T FH (follicular helper) and T CM (central memory) were also well-maintained in secondary passages in PDX models. Gene signatures of late PDX passages (3 rd-5 th) were enriched with genes related to proliferation and metabolic reprogramming, and in an independent cohort of AITLs, high expression of T3/T5 related signatures was associated with worse outcome (p=0.02/p=0.009). Low mRNA expression of PHLPP2 predicted poor prognosis (p=.03) and engineered PHLPP2 loss showed enhanced PI(3)K activation and FOXO1 inactivation in CD4+ T-cells in-vitro. Thus, we defined the genomic landscape for AITL, which is largely characterized by epigenetic alterations, TCR signaling and PI3K/AKT dysregulation, which may be amenable for therapeutic targeting.
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence
Wu, Gongwei , Yoshida, Noriaki , Liu, Jihe , Xiong, Yuan , Heavican‐Foral, Tayla B. , Mandato, Elisa , Nelson, Geoffrey M. , Yang, Lu , Chen, Renee , Jones, M. , Roshal, Mikhail , Zhang, Yanming , Xu, Ran , Jain, Salvia , Leahy, Catharine, Jones, Kristen L. , Stevenson, Kristen E. , Galasso, Natasha, Ganesan, Nivetha , Chang, Tiffany , Wu, Wenchao, Louissaint, Abner , Debaize, Lydie , Cin, Paola Dal , Chan, Wing C. , Sui, Shannan J. Ho , Ng, Samuel Y., Chen, Chun‐Wei , Weinstock, David M. , Zhang, Xiaoyang , Xiong, Yuan , Nelson, Geoffrey M , Yang, Lu , Donovan, Katherine A , Jones, Marcus K , Zhang, Yanming , Xu, Ran , Nirmal, Ajit J , Jain, Salvia , Ganesan, Nivetha , Chang, Tiffany , Dal Cin, Paola , Ho Sui, Shannan J , Feldman, Andrew L , Horwitz, Steven M , Adelman, Karen , Fischer, Eric S , Chen, Chun-Wei , Weinstock, David M , Brown, Myles , Heavican, Tayla B., Liu, Huiyun , Yoon, Hojong , Feldman, Andrew L. , Horwitz, Steven M. , Brown, Myles

Mayo Clinic

Science Translational Medicine | September 20, 2023 | Volume: 15 | Issue: 714 | Pages: No page available

10.1126/scitranslmed.adi7244 | PMID 37729434 Get It

Gene fusions involving tumor protein p63 gene (TP63) occur in multiple T and B cell lymphomas and portend a dismal prognosis for patients. The function and mechanisms of TP63 fusions remain unclear, and there is no target therapy for patients with lymphoma harboring TP63 fusions. Here, we show that TP63 fusions act as bona fide oncogenes and are essential for fusion-positive lymphomas. Transgenic mice expressing TBL1XR1::TP63, the most common TP63 fusion, develop diverse lymphomas that recapitulate multiple human T and B cell lymphomas. Here, we identify that TP63 fusions coordinate the recruitment of two epigenetic modifying complexes, the nuclear receptor corepressor (NCoR)—histone deacetylase 3 (HDAC3) by the N-terminal TP63 fusion partner and the lysine methyltransferase 2D (KMT2D) by the C-terminal TP63 component, which are both required for fusion-dependent survival. TBL1XR1::TP63 localization at enhancers drives a unique cell state that involves up-regulation of MYC and the polycomb repressor complex 2 (PRC2) components EED and EZH2. Inhibiting EZH2 with the therapeutic agent valemetostat is highly effective at treating transgenic lymphoma murine models, xenografts, and patient-derived xenografts harboring TP63 fusions. One patient with TP63 -rearranged lymphoma showed a rapid response to valemetostat treatment. In summary, TP63 fusions link partner components that, together, coordinate multiple epigenetic complexes, resulting in therapeutic vulnerability to EZH2 inhibition.
Abstract 5755: TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2
Wu, Gongwei , Liu, Jihe , Xiong, Yuan , Heavican‐Foral, Tayla B. , Yang, Lu , Chen, Renee , Jones, M. , Roshal, Mikhail , Zhang, Yanming , Xu, Ran , Jain, Salvia , Leahy, Catharine, Jones, Kristen L. , Stevenson, Kristen E. , Galasso, Natasha, Ganesan, Nivetha , Chang, Tiffany , Wu, Wenchao, Louissaint, Abner , Debaize, Lydie , Cin, Paola Dal , Chan, Wing Chan, Sui, Shannan Ho Sui Ho, Ng, Samuel Y., Meyerson, Mathew L., Weinstock, David M. , Yoshida, Noriaki , Zhang, Xiaoyang , Heavican, Tayla B., Liu, Huiyun, Nelson, Geoffrey M. , Donovan, Katherine A , Nirmal, Ajit J , Yoon, Hojong , Feldman, Andrew L. , Horwitz, Steven M. , Adelman, Karen , Fischer, Eric S , Chen, Chun‐Wei , Brown, Myles

Mayo Clinic

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5755-5755

10.1158/1538-7445.am2023-5755 Get It

Abstract Recurrent chromosomal rearrangements are a hallmark of hematologic malignancies and play critical roles in pathogenesis. The TP53 analog TP63 is rearranged in 5-10% of diverse subtypes of both aggressive T- and B-cell lymphomas. Patients with TP63-rearranged lymphomas have dismal outcomes, with 5-year overall survival rates between 0-17%, depending on cohorts. The function and mechanisms of TP63 rearrangements and TP63 fusion proteins in tumorigenesis are poorly understood. As a result, attempts to treat these patients to date have been largely empiric. Thus, there is an urgent need to understand how TP63 fusions contribute to tumorigenesis and to translate the findings into novel therapeutic options for these patients. Here, we demonstrated that TP63 fusions are essential for the propagation of T-cell lymphomas (TCLs). Knockdown of TP63 fusions with specific shRNAs in TCL cell lines harboring TP63 fusions suppressed both cell growth in vitro and tumor growth in vivo. Retroviral expression of TBL1XR1-TP63, the most common TP63 fusion, conferred cytokine independence in Ba/F3 cells, consistent with its role as an oncogene. To investigate the role of TP63 fusions in T- and B-cell lymphomagenesis, we engineered a CAG-Loxp-Stop-Loxp-TBL1XR1-TP63 conditional knock-in mouse model and crossed with hCD2-Cre mice. This results in expression beginning during early lymphoid development. As observed in patients, transgenic mice developed multiple subtypes of both T- and B-cell lymphoma. To define the effects and mechanisms of TP63 fusions within T cells, we performed CRISPR scanning, transcriptomic, epigenomic, and proteomic analyses. Our data showed that domains within both the N-terminal TBL1XR1 and C-terminal TP63 portions contribute to the function of this fusion. We found that the N-terminal component of TP63 fusions interacts with components of the NCOR/SMRT complex. At the same time, the C-terminal portion of TP63 (which recapitulates the deltaN-p63 isoform expressed in some carcinomas) interacts with the enhancer modifier KMT2D and its complex members. TBL1XR1-TP63 binds to a novel distal enhancer to drive MYC expression, and thus upregulates the expression of the histone H3K27 methylase EZH2. Finally, we assessed whether EZH2 is a vulnerability of TP63-rearranged lymphomas. We found that knockdown of EZH2 in TP63-rearranged lines significantly impaired cell growth, as did treatment with the EZH2 and 1 dual inhibitor valemetostat. Valemetostat, which is now being tested in patients with lymphoma, counteracted the oncogenic effects of TP63 fusions in multiple preclinical models in vivo. Together, our results identify the TP63 fusion as a highly unique oncogenic driver in lymphomagenesis capable of recruiting multiple epigenetic modifier complexes and inducing a targetable dependence on EZH2. Citation Format: Gongwei Wu, Noriaki Yoshida, Jihe Liu, Xiaoyang Zhang, Yuan Xiong, Tayla Heavican-Foral, Huiyun Liu, Geoffrey Nelson, Lu Yang, Renee Chen, Katherine Donovan, Marcus Jones, Mikhail Roshal, Yanming Zhang, Ran Xu, Ajit Nirmal, Salvia Jain, Catharine Leahy, Kristen Jones, Kristen Stevenson, Natasha Galasso, Nivetha Ganesan, Tiffany Chang, Wen-Chao Wu, Abner Louissaint, Lydie Debaize, Hojong Yoon, Paola Dal Cin, Wing Chan Chan, Shannan Ho Sui Ho Sui, Samuel Ng, Andrew Feldman, Steven M. Horwitz, Mathew Meyerson, Karen Adelman, Eric Fischer, Chun-Wei Chen, David Weinstock, Myles Brown. TP63 fusions drive enhancer rewiring, lymphomagenesis, and dependence on EZH2. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5755.
Genomic profiling for clinical decision making in lymphoid neoplasms
Leval, Laurence de , Alizadeh, Ash A. , Bergsagel, P. Leif , Campo, Elı́as , Davies, Andrew , Doǧan, Ahmet , Fitzgibbon, Jude , Horwitz, Steven M. , Melnick, Ari , Morice, William G. , Nadel, Bertrand , Rosenquist, Richard , Rossi, Davide , Advani, Ranjana H. , Allen, Carl E. , Ansell, Stephen M. , Chan, Wing C. , Cook, James R. , Cook, Lucy , d’Amore, Francesco, Dirnhofer, Stefan , Dreyling, Martin , Dunleavy, Kieron , Hodson, Daniel J. , Klapper, Wolfram , Kim, Won Seog , King, Rebecca L. , Ko, Young Hyeh , LaCasce, Ann S. , Lenz, Georg , Pasqualucci, Laura , Rosenwald, Andreas , Miguel, Jesús F. San , Staudt, Louis M. , Weigert, Oliver , Wilson, Wyndham H. , Wu, Catherine J. , Bagg, Adam , Dirnhofer, S , Bergsagel, P. Leif , de Leval, Laurence , Melnick, Ari , Morin, Ryan D , Nadel, Bertrand , Pileri, Stefano , Rosenquist, Richard , Salaverria, Itziar , Steidl, Christian , Treon, Steven , Zelenetz, Andrew D , Allen, Carl E , Ansell, Stephen M , Chan, Wing C , Cook, James R , Cook, Lucy B , d'Amore, Francesco , Dreyling, Martin , Dunleavy, Kieron , Feldman, Andrew L , Fend, Falko , Gaulard, Philippe , Ghia, Paolo , Gribben, John G. , Hermine, Olivier , Hodson, Daniel J , Hsi, Eric D , Inghirami, Giorgio , Jaffe, Elaine S , Karube, Kennosuke , Kataoka, Keisuke , Klapper, Wolfram , King, Rebecca L , Hyeh, Young , LaCasce, Ann Steward , Lenz, Georg , Piris, Miguel , Pittaluga, Stefania , Pasqualucci, Laura , Quintanilla-Martinez, Leticia , Rodig, Scott J , Rosenwald, Andreas , Salles, Gilles A , San-Miguel, Jesus , Savage, Kerry J , Sehn, Laurie H , Semenzato, Gianpietro , Staudt, Louis M , Swerdlow, Steven H , Tam, Constantine S , Trotman, Judith , Vose, Julie , Weigert, Oliver , Wilson, Wyndham H , Winter, Jane N , Wu, Catherine J , Zinzani, Pier Luigi , Zucca, Emanuele , Bagg, Adam , Scott, David W , Morice, William George , Campo, Elías , Advani, Ranjana H , Dogan, Ahmet , Davies, Andrew , Fitzgibbon, Jude , Horwitz, Steven M , Alizadeh, Ash A , Pileri, Stefano , Salaverría, Itziar , Steidl, Christian , Treon, Steven P. , Zelenetz, Andrew D. , Feldman, Andrew L. , Ghia, Paolo , Hermine, Olivier , Hsi, Eric D. , Inghirami, Giorgio , Jaffe, Elaine S. , Karube, Kennosuke , Martin-Subero, Jose Ignacio , Piris, Miguel Á. , Pittaluga, Stefania , Quintanilla‐Martínez, Leticia , Salles, Gilles , Savage, Kerry J. , Sehn, Laurie H. , Swerdlow, Steven H. , Tam, Constantine S. , Vose, Julie M. , Winter, Jane N. , Zinzani, Pier Luigi , Zucca, Emanuele , Scott, David W.

Mayo Clinic

Blood | August 24, 2022 | Volume: 140 | Issue: 21 | Pages: 2193-2227

10.1182/blood.2022015854 | PMID 36001803 Get It

Abstract With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for the classification and diagnosis of these disorders, founded on a multidimensional definition of disease entities, have been consolidated over the past 25 years, novel genomic data have markedly enhanced our understanding of lymphomagenesis and enriched the description of disease entities at the molecular level. Yet, the current diagnosis of lymphoid tumors is largely based on morphological assessment and immunophenotyping, with only few entities being defined by genomic criteria. This paper, which accompanies the International Consensus Classification of mature lymphoid neoplasms, will address how established assays and newly developed technologies for molecular testing already complement clinical diagnoses and provide a novel lens on disease classification. More specifically, their contributions to diagnosis refinement, risk stratification, and therapy prediction will be considered for the main categories of lymphoid neoplasms. The potential of whole-genome sequencing, circulating tumor DNA analyses, single-cell analyses, and epigenetic profiling will be discussed because these will likely become important future tools for implementing precision medicine approaches in clinical decision making for patients with lymphoid malignancies.
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice
Amador, Catalina , Wright, George W. , Weisenburger, Dennis D. , Greiner, Timothy C. , Lone, Waseem , Heavican, Tayla B., Smith, Lynette M. , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Rosenwald, Andreas , Slack, Graham W. , Kim, Won Seog , Hyeh, Young, Li, Yuping , Dong, Gehong, Ondrejka, Sarah L. , Cook, James R. , Lim, Soon Thye , Ong, Choon Kiat , Chapman, Jennifer R. , Raess, Philipp W. , Blombery, Piers , Morris, Stephan W., Staudt, Louis M. , Chan, Wing C. , Iqbal, Javeed , Greiner, Timothy C , Heavican, Tayla B , Smith, Lynette , Pileri, Stefano , Tabanelli, Valentina , Ott, German , Savage, Kerry J , Kim, Won Seog , Hyeh, Young , Song, Joo Y , Ondrejka, Sarah , Cook, James R , Lim, Soon Thye , Ong, Choon Kiat , Inghirami, Giorgio , Raess, Philipp W , Gould, Clare , Jaffe, Elaine S , Vose, Julie , Chan, Wing C , Iqbal, Javeed , Amador, Catalina , Lone, Waseem G , Wright, George , Bouska, Alyssa , Feldman, Andrew L. , Savage, Kerry J. , Ko, Young Hyeh , Song, Joo Y. , Barrionuevo, Carlos , Inghirami, Giorgio , Bhagavathi, Sharathkumar , Gould, Clare , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Journal of Clinical Oncology | July 15, 2022 | Volume: 40 | Issue: 36 | Pages: 4261-4275

10.1200/jco.21.02707 | PMID 35839444 Get It

PURPOSE Peripheral T-cell lymphoma (PTCL) includes heterogeneous clinicopathologic entities with numerous diagnostic and treatment challenges. We previously defined robust transcriptomic signatures that distinguish common PTCL entities and identified two novel biologic and prognostic PTCL-not otherwise specified subtypes (PTCL-TBX21 and PTCL-GATA3). We aimed to consolidate a gene expression–based subclassification using formalin-fixed, paraffin-embedded (FFPE) tissues to improve the accuracy and precision in PTCL diagnosis. MATERIALS AND METHODS We assembled a well-characterized PTCL training cohort (n = 105) with gene expression profiling data to derive a diagnostic signature using fresh-frozen tissue on the HG-U133plus2.0 platform (Affymetrix, Inc, Santa Clara, CA) subsequently validated using matched FFPE tissues in a digital gene expression profiling platform (nCounter, NanoString Technologies, Inc, Seattle, WA). Statistical filtering approaches were applied to refine the transcriptomic signatures and then validated in another PTCL cohort (n = 140) with rigorous pathology review and ancillary assays. RESULTS In the training cohort, the refined transcriptomic classifier in FFPE tissues showed high sensitivity (> 80%), specificity (> 95%), and accuracy (> 94%) for PTCL subclassification compared with the fresh-frozen–derived diagnostic model and showed high reproducibility between three independent laboratories. In the validation cohort, the transcriptional classifier matched the pathology diagnosis rendered by three expert hematopathologists in 85% (n = 119) of the cases, showed borderline association with the molecular signatures in 6% (n = 8), and disagreed in 8% (n = 11). The classifier improved the pathology diagnosis in two cases, validated by clinical findings. Of the 11 cases with disagreements, four had a molecular classification that may provide an improvement over pathology diagnosis on the basis of overall transcriptomic and morphological features. The molecular subclassification provided a comprehensive molecular characterization of PTCL subtypes, including viral etiologic factors and translocation partners. CONCLUSION We developed a novel transcriptomic approach for PTCL subclassification that facilitates translation into clinical practice with higher precision and uniformity than conventional pathology diagnosis.